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Abstract Polyketides, such as erythromycin, are complex
natural products with diverse therapeutic applications. They
are synthesized by multi-modular megaenzymes, so-called
polyketide synthases (PKSs). The macrolide core of erythro-
mycin, 6-deoxyerythronolide B (6dEB), is produced by the
deoxyerythronolide B synthase (DEBS) that consists of three
proteins each with a size of 330–370 kDa. We cloned and
investigated the expression of the corresponding gene cluster
from Saccharopolyspora erythraea, which comprises more
than 30 kb, in Bacillus subtilis. It is shown that the DEBS
genes are functionally expressed in B. subtiliswhen the native
eryAI–III operon was separated into three individual expres-
sion cassettes with optimized ribosomal binding sites. A syn-
thesis of 6dEB could be detected by using the acetoin-
inducible acoA promoter and a fed-batch simulating
EnBase-cultivation strategy. B. subtilis was capable of the
secretion of 6dEB into the medium. In order to improve the
6dEB production, several genomic modifications of this pro-
duction strain were tested. This included the knockout of the
native secondary metabolite clusters of B. subtilis for the syn-
thesis of surfactin (26 kb), bacillaene (76 kb), and plipastatin
(38 kb). It is revealed that the deletion of the prpBD operon,
responsible for propionyl-CoA utilization, resulted in a signif-
icant increase of the 6dEB product yield when exogenous
propionate is provided. Although the presented B. subtilis
6dEB production strain is not competitive with established
Escherichia coli 6dEB production strains, the results of this
study indicate that B. subtilis is a suitable heterologous host
for the secretory production of a complex polyketide.
Keywords Bacillus subtilis . Deoxyerythronolide B
synthase . Heterologous expression . Polyketide . acoA
promoter .Metabolic engineering
Introduction
The broad-spectrum antibiotic erythromycin, produced by the
actinomycete Saccharopolyspora erythraea, is a well-studied
representative of a class of complex natural products called
polyketides (Corcoran 1981). Its macrolide core, 6-
deoxyerythronolide B (6dEB), is synthesized by a polyketide
synthase (PKS) that has emerged as the prototypical modular
megasynthase (Khosla et al. 2007).
In general, PKSs can assemble complex biomolecules from
simple building blocks such as malonyl coenzym A (malonyl-
CoA), methylmalonyl-CoA, and propionyl-CoA through an
assembly line thiotemplate mechanism (Cane and Walsh
1999). As a result of the variety of number and type of incor-
porated units in combination with the possible partial or com-
plete reduction of each keto-function and further (also post-
enzymatic) modifications of the metabolite, this group of
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natural products shows an enormous degree of structural di-
versity. This in turn results in the extraordinary variety of
biological properties and is the reason for the significance of
this group, especially for pharmaceutical applications.
Unfortunately, natural sources can in many cases not cover
the increasing demand for new bioactive natural products
(Koehn and Carter 2005). Due to the structural complexity
of polyketides, synthetic routes are precluded and the devel-
opment of fermentation processes is necessary to allow suffi-
cient production for pre-clinical and clinical studies. Quite
often, success is closely linked with the selection of a suitable
surrogate host. But, for heterologous polyketide biosynthesis,
three challenges have to be addressed. First, the entire gene
cluster needs to be functionally transferred. Second, the pro-
teins have to be expressed, correctly folded, and post-
translationally modified. To this purpose, a universal
phosphopantetheinyl transferase (PPTase) is required for
pantetheinylation and thus activation of the PKS (Lambalot
et al. 1996). Third, metabolic building blocks must be avail-
able. For example, the corresponding gene cluster for 6dEB
synthesis comprises three genes of approximately 10 kb
(eryAI–III). They encode for three large proteins, denoted
DEBS1, DEBS2, and DEBS3, that show a size of 330–
370 kDa each and form an enzymatic complex. Along this
protein complex, there are 28 active sites that are precisely
arranged and responsible for the stepwise combination and
modification of one propionyl-CoA primer unit and six (2S)-
methylmalonyl-CoA extender units (Fig. S1 in the Supple-
mentary Material) (Khosla et al. 2007). Furthermore, with
regard to the industrial production of drugs, many safety re-
quirements which are regulated and controlled by the Europe-
an Medicine Agency (EMA) or the Food and Drug Adminis-
tration (FDA) have to be considered.
The Gram-positive, non-pathogenic strain Bacillus subtilis
can fulfill these safety requirements as it owns the Generally
Recognized As Safe (GRAS) status and the Qualified Pre-
sumption of Safety (QPS) certification (Leuschner et al.
2010; Sietske de Boer and Diderichsen 1991). Due to the
absence of lipopolysaccharides on the outer cell membrane,
which are a typical feature of Gram-negative hosts such as
Escherichia coli and act as endotoxins, the downstream pro-
cess is simplified and thus less cost intensive (Petsch and
Anspach 2000). Furthermore, because of its natural ability to
secrete peptides into the culture environment, which also fa-
cilitates downstream processing, B. subtilis is one of the most
important strains for industrial enzyme production (van Dijl
and Hecker 2013).
For heterologous production of secondary metabolites, it is
especially noteworthy thatB. subtilis, in contrast toE. coli, is a
natural producer of several bioactive compounds (Stein 2005).
The antibiotically effective bacillaene, which is synthesized
via a PKS/non-ribosomal peptide synthetase (NRPS)-hybrid
pathway, is one representative (Patel et al. 1995; Butcher et al.
2007). Two other examples are the non-ribosomal lipopeptide
surfactin (Arima et al. 1968; Nakano et al. 1991) and
plipastatin (Tsuge et al. 2007) with antimicrobial activities.
Furthermore, with the secretory production of the peptide an-
tibiotic bacitracin from Bacillus licheniformis (Eppelmann
et al. 2001) as well as the cyclohexadepsipeptide enniatin from
Fusarium oxysporum showing various antimicrobial effects
(Zobel et al. 2015), the suitability of B. subtilis as a heterolo-
gous host for non-ribosomal peptide–type compounds could
already be demonstrated.
To evaluate the suitability of B. subtilis as a heterologous
host for the engineered biosynthesis of polyketides, we chose
the already mentioned and well-investigated macrolide 6dEB
as a model compound. Since this metabolite needs to be acti-
vated by several post-PKSmodifications, it does not show any
antibiotic effect that could inhibit the host. Furthermore, al-
though heterologous production was already demonstrated in
Streptomyces coelicolor (Kao et al. 1994) and E. coli (Pfeifer
et al. 2001, 2002), there was an interest in extending the list of
heterologous hosts further in anticipation of future biosynthet-




Unless stated otherwise, all chemicals were purchased from
Roth (Karlsruhe, Germany) at the highest purity available and
were used without further purification. Oligonucleotides
(listed in Table S1 in the Supplementary Material) were syn-
thesized and provided by Life Technologies (Darmstadt, Ger-
many). All plasmids and strains used in this study are listed in
Tables 1 and 2, respectively. Relevant translational and tran-
scriptional elements of the native and modified eryAI–III gene
cassettes are summarized in Table 3. All cloning procedures
were carried out in E. coli DH10B (Invitrogen, Darmstadt,
Germany) [F- endA1 recA1 galE15 galK16 nupG rpsL
ΔlacX74 Φ80lacZΔM15 araD139 Δ(ara,leu)7697 mcrA
Δ(mrr-hsdRMS-mcrBC) λ-]. Restriction enzymes and other
DNA-modifying enzymes were used as specified by the sup-
plier (New England Biolabs, Frankfurt, Germany). PCR prod-
ucts were purified with the High Pure PCR Product Purifica-
tion Kit (Roche, Mannheim, Germany). Plasmid isolation was
performed using the High Pure Plasmid Isolation Kit (Roche,
Mannheim, Germany). For gel extraction, the QIAquick Gel
Extraction Kit from Qiagen (Hilden, Germany) was used. Re-
combinant B. subtilis strains were verified by colony PCR as
previously described (Kumpfmüller et al. 2013). All plasmid
constructs (see Supplementary Material) and chromosomal
integrations were verified by sequencing carried out by
Eurofins Genomics (Elbersberg, Germany).
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Construction of strains
In this study, an optimized protocol for rapid and multiple
genome modification of B. subtilis was used which was pre-
viously described (Kumpfmüller et al. 2013). For comS induc-
tion, 100 μM isopropyl-β-D-thiogalactoside (IPTG) was
added when the cells were diluted. Unless stated otherwise,
the antibiotic selection marker was removed after successful
chromosomal integration using a method based on the recom-
bination of flanking lox sites with chromosomally localized
cre as described in the above mentioned protocol. For
B. subtilis, antibiotics were used in the following final con-
centrations: 100 μg/mL spectinomycin, 20 μg/mL kanamy-
cin, and 20 μg/mL zeocin.
Table 1 Plasmids used in this study
Plasmid Function Reference




Integration of genes into the amyE locus with lox-SSS-cassette Kumpfmüller et al. (2013)
pAMY-Spec Integration of genes into the amyE locus with remaining SpecR-cassette Kumpfmüller et al. (2013)
pAMY-SSS Integration of genes into the amyE locus with SSS-cassette Kumpfmüller et al. (2013)
pJET-lox-SSS Source of lox-SSS-cassette Kumpfmüller et al. (2013)
pJK64a Reconstitution of genetic sfp defect with lox-SSS-cassette Zobel et al. (2015)
pJK93 Deletion of srfA operon with remaining KanR-cassette Zobel et al. (2015)
pJK94 Deletion of srfA operon with remaining SpecR-cassette This study
pJK111 Deletion of srfA operon with SSS-cassette This study
pJK119 Integration of eryAI with acoA-promoter in srfA gene locus (SpecR-cassette) This study
pJK119c Integration of eryAI with acoA-promoter in srfA gene locus (lox-SSS-cassette) This study
pJK123 Deletion of srfA operon with remaining KanR-cassette Kumpfmüller, unpublished
pJK126 Deletion of srfA operon with remaining NmR-cassette Kumpfmüller, unpublished
pJK134 Deletion of srfA operon with remaining KanR and CmR for RedET cloning This study
pJK139 Integration of eryAII with acoA-promoter in srfA gene locus (KanR-cassette) This study
pJK139a Integration of eryAII with acoA-promoter in srfA gene locus (KanR- and lox-SSS-cassette) This study
pJK140 Integration of eryAII with RBS in srfA gene locus (KanR-cassette) This study
pJK140a Integration of eryAII with RBS in srfA gene locus (KanR- and lox-SSS-cassette) This study
pJK155 Integration of wild-type eryAI–III-cluster with acoA-promoter in srfA gene locus This study
pJK179 Deletion of pksX operon Zobel et al. (2015)
pJK191 Deletion of srfA operon Zobel et al. (2015)
pJK205 Insertion in lytC gene locus Zobel et al. (2015)
pJK206 Deletion of srfA operon with KanR- and lox-SSS-cassette This study
pJK209 Deletion of spoIIGA gene Zobel et al. (2015)
pJK219 Toolbox-plasmid for integration of CDS with acoA-promoter in srfA gene locus (lox-SSS-
cassette)
This study
pJK226 Deletion of restriction and modification system Zobel et al. (2015)
pJK245 Integration of eryAIII with acoA-promoter in srfA gene locus This study
pJK246 Integration of eryAIII with RBS in srfA gene locus This study
pJK254 Deletion of pps operon This study
pJK257 Integration of ery-orf5 with acoA-promoter in srfA gene locus This study
pJK258 Integration of ery-orf5 with acoA-promoter in srfA gene locus, in addition to eryAI–III-cluster This study
pJK260 Deletion of prp operon This study
pMSE3 High-copy E. coli/B. subtilis shuttle vector with KanR-cassette Silbersack et al. (2006)
CmR chloramphenicol resistance cassette, KanR kanamycin resistance cassette, NmR neomycin resistance cassette, SpecR spectinomycin resistance
cassette, ss six site, SSS SpecR flanked by two ss, lox-SSS SSS surrounded by a lox71 and lox66 site
a The cosmid P1394 was received from the cosmid library of the Peter Leadlay laboratory from the Department of Biochemistry at the University of
Cambridge. The cosmid sequence with the eryAI–III-cluster can be found on the BSaccharopolyspora erythraea genome project web site^ at http://131.
111.43.95/gnmweb/index.html.
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Media and cultivation
For expression studies,B. subtilis strains were cultivated in the
fed-batch simulating EnBase® system from BioSilta. To this
purpose, the EnPresso B Tablet Cultivation Set was used in
combination with 24-well deepwell culture plates and
airporous seals for multi-well plates (all BioSilta, Oulu,
Finland). For cultivation, 2 mL of prepared medium (includ-
ing 0.1 % acetoin for promoter induction, 1.5 U/L Reagent A
for enzyme-based substrate delivery, 20 μg/mL zeocin for
selection, and 20 mM sodium propionate as 6dEB precursor,
if not indicated otherwise) was inoculated with 100 μL of a
late-exponential pre-culture (LB medium; 37 °C, OD600
approx. 2.0) and incubated at 30 °C at 250 rpm (25-mm
Table 2 Strains used in this study
Strain Relevant genotype Reference
B. subtilis 168 Wild type, sfp0 Zeigler et al. (2008)
B. subtilis
JK13
ΔsacA::(ZeoR, Pspac-comS, lacI, PxylA-cre, xylR) Zobel et al. (2015)
B. subtilis
JK34












BsJK47+ΔsrfA::(PacoA-eryAI-T7, PacoA- eryAII, Kan
R, lox72) This study
B. subtilis
JK58



















R, lox72) This study
B. subtilis
JK65































KanR kanamycin resistance cassette, SpecR spectinomycin resistance cassette, ZeoR zeocin resistance cassette, ss six site, lox72 lox72 site
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amplitude). After overnight culture (16 h), 200 μL of the dis-
solved booster solution and another 1.5 U/L Reagent A were
added and the cultivation was continued for 48 h under shak-
ing conditions.
RNA isolation and analysis
RNA isolation was done as previously described (Welsch
et al. 2012). For slot blot analyses, the Bio-Dot SF
Microfiltration Apparatus (Bio-Rad, Munich, Germany) was
used according to the manufacturer’s protocol. RNA probes
were prepared using the DIG RNA Labeling Kit (SP6/T7)
from Roche Life Science (Mannheim, Germany) and the fol-
lowing primers: eryAI, 5056/5490; eryAII, 5105/5496; and
eryAIII, 5492/5493. Hybridization and detection were per-
formed as described elsewhere (Welsch et al. 2012).
Extraction
After cultivation, the cells were harvested and 1300 μL of the
supernatant was supplemented with 13 μL of internal standard
m ix t u r e ( 1 ng /μL su l f a d ime t hox i n e , 2 ng /μL
sulfachloropyridazine in methanol, HPLC grade). Subse-
quently, samples were extracted with an equal volume of ethyl
acetate and agitated for 10 min at 30 °C. Phase separation was
performed via centrifugation at room temperature and
8500 rpm for 5 min. After ethyl acetate was evaporated under
vacuum, the extracts were dissolved in 75 μL HPLC-grade
methanol for HPLC-mass spectrometry (MS) analysis.
HPLC and mass spectrometry
All experiments were carried out on an Agilent 1200 HPLC
system coupled to a 6460 Triple Quadrupole mass spectrom-
eter equipped with a Jet stream ESI-source (Agilent Technol-
ogies, Waldbronn, Germany). The chromatographic separa-
tion was achieved temperature controlled at 25 °C on a
Synergi Fusion-RP column (2.5 μm, 50×2.0 mm) equipped
with a pre-column of the samematerial (4×2.0 mm) both from
Phenomenex (Aschaffenburg, Germany). A gradient of mo-
bile phase A (0.1 % formic acid) and mobile phase B
(acetonitrile) was used as shown in Table S2 in the Supple-
mentary Material (flow rate of 0.5 mL/min, injection volume
of 10 μL). The MS was operated in positive ion mode with
multi-reaction monitoring (MRM). The MS/MS fragmenta-
tion pattern of 6dEB and the internal standard compounds
were determined and the MS parameters were optimized.
The optimized source parameters are displayed in Table S3
in the Supplementary Material.
6dEB was monitored with transitions m/z 409.1 to m/z
311.2 for relative quantification and m/z 409.1 to m/z 391.2
and m/z 293.2 for identification. Collision energies for the
transitions of 6dEB were 25, 21, and 25 V, respectively. Data
was acquired and evaluated using the Mass Hunter software;
quantitative analysis was done using Mass Hunter Quantita-
tive Analysis (version B03.02, Agilent Technologies,
Waldbronn, Germany).
6dEB quantification
For quantification of 6dEB titers, the culture volume was in-
creased to 100 mL, and 500-mL Ultra Yield Flasks with the
according AirOTop Seals (BioSilta, Oulu, Finland) were used.
Supplementation, induction, inoculation, and cultivation were
performed as mentioned above. Metabolites form these cul-
tures were extracted twice with 100mL ethyl acetate and dried
with sodium sulfate afterward. After evaporation of the sol-
vent, the extracts were quantified as described elsewhere
(Zhang et al. 2015).
Results
Construction of the DEBS expression strains
All plasmids for integration of the eryAI–III genes are present-
ed in Fig. S2 in the Supplementary Material. The construction
of these plasmids is explained in the Supplementary Material
Table 3 Transcriptional and
translational elements of the
native and the modified eryAI–III
gene cassettes
Strain mRNA Gene RBS ← Distance→ Start codon Stop codon
B. subtilis JK59-1 monocistronic eryAI GGAGGA 7 bp ATG TAA
eryAII GGAGGA 7 bp ATG TAA
eryAIII GGAGGA 7 bp ATG TAA
B. subtilis JK66-1 tricistronic eryAI GGAGGA 7 bp ATG TAA
eryAII GGAGGA 7 bp ATG TAA
eryAIII GGAGGA 7 bp ATG TAA
B. subtilis JK71-1 tricistronic eryAI GGAGGA 7 bp ATG TGA
eryAII TGGAGA 4 bp GTG TAG
eryAIII AGAGGA 7 bp ATG TAA
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text and by Fig. S3 in the Supplementary Material. The
starting strain used in this study was B. subtilis JK13
(Zobel et al. 2015), a derivative of the Marburg 168
strain, which already contained an IPTG-inducible second
gene copy of the competence factor ComS for enhanced
transformation efficiency and the xylose-inducible cre
gene for marker removal.
In order to investigate the expression of the eryI-III
gene cluster from Saccharopolyspora erythraea, which
comprises more than 30 kb, in B. subtilis, the DEBS
genes were localized to the B. subtilis JK13 chromo-
some in three different cluster organizations: (A) native
operon, (B) native operon with optimized ribosomal
binding sites, and (C) the three native ery gene se-
quences as separate cassettes with optimized ribosomal
binding sites. The operons and the individual gene cas-
settes were set under control of the acetoin inducible
acoA promoter.
Due to a frame shift mutation in the PPTase sfp gene,
B. subtilis 168 strains are not able to activate NRPS and
PKS enzymes (Mootz et al. 2001). Hence, they do not
produce hemolytic surfactin and deletion of the corre-
sponding srfA operon cannot be detected on sheep
blood agar plates. In order to allow simple screening
for positive transformants after chromosomal integration
of the eryAI–III genes in the srfA gene locus, first a
KanR-cassette was inserted by chromosomal integration
of pJK206 in B. subtilis JK13. The resulting strain
B. subtilis JK34 was then treated with linearized
pJK119c to chromosomally integrate the PacoA-eryAI-
TT7-operon thereby replacing the Kan
R gene. Thus, the
obtained eryI-positive colonies could be screened for
loss of kanamycin resistance. For further integration of
the eryAII gene, the restriction and modification (RM)
system (namely, ydzT–W, ydiP–S, and ydjA–C) of the
resulting strain (B. subtilis JK53) had to be deleted by
chromosomal integration of pJK226 to give B. subtilis
JK54. The positive effect of this knockout (higher trans-
formation efficiency with large DNA fragments) was
already described elsewhere (Choi et al. 2009; Haima
et al. 1987). Hereafter, B. subtilis JK54 was transformed
with plasmid pJK139a, resulting in B. subtilis JK57.
Thereby, a KanR-cassette was introduced together with
the PacoA-eryAII-operon allowing screening for another
resistance switch after the following chromosomal inte-
gration of the PacoA-eryAIII-TT7-operon by using
pJK245. Hence, the resulting strain B. subtilis JK58
harbored all three eryA genes as distinct cassettes, each
under the control of the acoA promoter (Ali et al.
2001). In a final step, sfp activity was reconstituted by
chromosomal integration of pJK64a, giving B. subtilis
JK59. The stepwise construction of this strain is shown
in Fig. 1.
For chromosomal integration of the modified eryAI–III op-
eron with optimized ribosomal binding sites, B. subtilis JK54
was used (see also Fig. 1). The RBS-eryAII-cassette was chro-
mosomally introduced together with a KanR-cassette by using
pJK140a and thereby removing the T7-terminator of the P-
acoA-eryAI-TT7-operon resulting in B. subtilis JK64. Hereafter,
pJK246 was used for chromosomal integration of the eryAIII
gene with optimized RBS to complete the PacoA-eryAI-RBS-
eryAII-RBS-eryAIII-TT7-operon. Due to the subsequent dele-
tion of the KanR-cassette the obtained colonies could be
screened for antibiotic resistance switch. For reconstitution
of the required sfp gene, this strain (B. subtilis JK65) was then
transformed with pJK64a to give B. subtilis JK66 (Fig. S4 in
the Supplementary Material).
A chromosomal integration of the 30-kb large wild-type
eryAI–III-cluster could be done in a single step only after
deletion of the RM system. Thus, pJK226 was used to trans-
form B. subtilis JK34 to give the kanamycin-resistant
B. subtilis JK47 strain. Hereafter, this mutant strain was treat-
ed with pJK155 thereby replacing the KanR-cassette. Positive
clones could be screened for the selection marker switch. For
subsequent marker removal, recombination of the flanking
six-sites with a plasmid-coded β-recombinase was performed
as described elsewhere (Kabisch et al. 2012) resulting in
B. subtilis JK70, which carries the PacoA-eryAI–IIInat-TT7-op-
eron. Again, this strain was then transformed with pJK64a for
sfp reconstitution giving B. subtilis JK71 (Fig. S5 in the Sup-
plementary Material).
Since the fed-batch simulating EnBase® system, which
was used for expression studies, is based on the enzymatic
release of glucose from a polymer, the amyE gene coding
for the α-amylase had to be knocked out to avoid interference
with the tightly controlled substrate delivery by an artificially
added amylase. For this purpose, pAMY-lox-SSS was used to
chromosomally delete the amyE locus of B. subtilis JK59,
JK66, and JK71 to give the amylase-negative strainsB. subtilis
JK59-1, JK66-1, and JK71-1, respectively.
Cultivation of DEBS expression strains and detection
of 6dEB production
All three expression strains were cultivated under fed-batch
simulating conditions and showed a similar growth behavior
that differed from the negative control beginning from t=40 h
(24 h post-boostering, see Fig. 2a). This observed reduced cell
growth could be a hint for the induced gene expression in
these recombinant strains. To qualify specific messenger
RNA (mRNA) production, RNA isolation followed by a slot
blot analysis was performed. The results indicated that the
eryAI–III genes were transcribed in all three B. subtilis strains
independent of the cluster organization (Fig. S6 in the Supple-
mentary Material). However, significant 6dEB production
could only be detected for BsJK59-1 which harbored the
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DEBS genes in three separate cassettes (Fig. 2b). For this
strain, it could also be revealed that relative 6dEB yield was
more than doubled by prolongation of the EnBase-based cul-
tivation to 48 h after boostering (data not shown).
Furthermore, it could be shown that the metabolite is
completely secreted, because no 6dEB could be detected in
an extract obtained from the cell pellet treated by sonification
(data not shown).
Fig. 1 Integration of eryAI, eryAII, and eryAIII as three individually
controlled genes with optimized RBS in B. subtilis JK34. Schematic
diagram (not to scale) showing the construction of B. subtilis JK59. a The
former srfA gene locus in the chromosome of B. subtilis JK34.
Transformation of this strain with pJK119c and subsequent recombination
of the lox sites via Cre resulted in B. subtilis JK53 (b). Deletion of the RM
system via pJK226 resulted in B. subtilis JK54 (c). Stepwise chromosomal
integration of the eryAII and eryAIII genes under control of the acoA
promoter via pJK139a and pJK245 resulted in B. subtilis JK57 (d) and
B. subtilis JK58 (e), respectively. In a final step, the frame shift mutated
sfp0 gene was chromosomally replaced by the native sfp+ gene by using
pJK64a to give B. subtilis JK59 (f). Thus, PPTase activity of Sfp was
reconstituted
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Optimization of 6dEB production in B. subtilis BsJK59-1
by engineering the genetic background
For potential optimization of 6dEB production, further genome
modifications were investigated. First, the DEBS-specific type
II thioesterase (TEII) encoded by the ery-orf5 gene was chro-
mosomally integrated in B. subtilis JK59-1 by using pJK258 to
give B. subtilis JK60. This accessory enzyme is known to in-
crease 6dEB production in the native producer as well as in the
surrogate E. coli host (Pfeifer et al. 2002). For enhanced cell
growth during heterologous protein production, this strain was
then transformed with pJK205 to generate a lytC knockout
mutant B. subtilis JK62 (Kabisch et al. 2012). Hereafter,
spoIIGA (involved in sporulation) was deleted by chromosomal
integration of pJK209 to give the sporulation-deficient strain
B. subtilis JK63. In order to reduce the metabolic burden of
the host, two gene clusters involved in secondary metabolite
production were removed from the chromosome in addition to
the srfAA–D operon. To this purpose, the pksA–R operon
(~76 kb) was deleted by using pJK179 resulting in B. subtilis
JK68, which was not able to produce the polyketide bacillaene.
In a next step, this strain was transformed with pJK254 to give
B. subtilis JK120 with a deletion of the 38 kb ppsA–E cluster,
coding for the plipastatin synthetase (NRPS).
The highest growth rate could be detected for B. subtilis
JK62 (DEBS1–3, TEII, ΔlytC), followed by B. subtilis JK60
(DEBS1–3, TEII). B. subtilis JK63 (DEBS1–3, TEII, ΔlytC,
ΔspoIIGA) and JK68 (DEBS1–3, TEII, ΔlytC, ΔspoIIGA,
ΔpksX) both resulted in a similar cell density compared to
the control strain JK62. It is interesting to note that the un-
modified 6dEB producer B. subtilis JK59-1 and the B. subtilis
JK120 strain, showing all mentioned modifications, revealed
the lowest maximal optical densities (see Fig. 3a).
According to the productivity, the relative 6dEB yield was
reduced from 100% inB. subtilis JK59-1 to 69% inB. subtilis
JK60 by introduction of the TEII. The additional deletion of
lytC resulted in the compensation of this negative effect,
whereby B. subtilis JK62 reached a similar relative 6dEB
yield. The spoIIGA knockout in B. subtilis JK63 resulted in
a further enhanced productivity (132 %), which was not af-
fected by the additional deletion of the pksA–R operon in
B. subtilis JK68 (129 %). Best results could be obtained with
B. subtilis JK120 that also showed the deletion of the ppsA–E
operon and yielded 143 % (Fig. 3b).
Influence of the modification of the propionyl-CoA
metabolism
To optimize the propionyl-CoAmetabolism with regard to the
6dEB production, the prpBD operon in B. subtilis JK120 re-
sponsible for propionyl-CoA utilization was deleted by using
pJK260, resulting in B. subtilis JK125. In addition to this
modification, the removal of propionate, which had always
been provided as supplementation, was also investigated.
In general, the cell growth was slightly increased during the
cultivation without propionate. Furthermore, the B. subtilis
JK125 strain reached higher cell densities compared to
B. subtilis JK120 (Fig. 4a).
Supplementing the medium with 20 mM sodium propionate
resulted in an increase in the relative 6dEB yield of 20 % for
B. subtilis JK120 and 75 % in case of the prpBD mutant strain
B. subtilis JK125. In addition, in the presence of propionate, the
relative 6dEB yield in B. subtilis JK125 was increased 2.5-fold
compared to that in B. subtilis JK120. In contrast, the deletion
of the prpBD operon resulted in a reduced 6dEB productivity
(−30 %) in the unsupplemented medium (Fig. 4b).
B. subtilis JK125, which has emerged as the best producer,
was chosen to quantify the level of 6dEB production. Without
further optimization of the culture conditions, a final 6dEB
concentration of 2.6±0.3 μg/L was reached with this strain.
Discussion
Although the DEBS genes could be localized in the chromo-
some of B. subtilis in three different cluster organizations (A,
Fig. 2 Comparison of engineered B. subtilis strains carrying the DEBS
genes in different cluster organizations. a Growth curves (OD600) during
cultivation for 64 h (16 h pre- plus 48 h post-boostering) in EnBase®
medium. b Quantitative MRM analysis of secreted 6dEB of modified
B. subtilis strains (t=48 h after boostering). BsJK59-1: three individually
controlled genes; BsJK66-1: one operon with modified RBS; BsJK71-1:
wild-type operon; BsJK84: negative control. N=3, therefore no quartiles,
but the median is shown
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native operon; B, modified native operon with optimized
RBS; and C, three separately transcribed genes with optimized
RBS) and specific mRNAs of eryAI, eryAII, and eryAIII could
be identified in all three expression strains, heterologous
6dEBproduction could only be detected in the strainB. subtilis
JK59-1, which controls the expression of the eryI-III genes by
three separate acoA promoters and optimized ribosomal bind-
ing sites. The ery mRNA analyses indicate that not the tran-
scription but the translation of the mRNAs is the critical step
in the heterologous expression of the 6dEB gene clusters. It
can be assumed that the monocistronic organization of the
eryAI, eryAII, and eryAIII genes in JK59-1 is the main reason
for the positive 6dEB synthesis as this is the only distinction to
B. subtilis JK66-1, which exhibits a tricistronic mRNA and no
detectable 6dEB titers. It could be speculated that a greater in-
stability or unfavorable secondary structures of the 30-kb
tricistronic mRNA in contrast to the 10-kb monocistronic
mRNAs result in insufficient translational initiation and/or un-
balanced expression levels of DEBS1, DEBS2, and DEBS3.
It is also demonstrated that only a fed-batch cultivation
strategy with the chosen acoA promoter system resulted in a
significant 6dEB biosynthesis. On the one hand, this might be
an effect of the higher cell densities that could be reached in
the fed-batch simulating EnBase medium. However, it is more
likely that it is a result of the linear cell growth that does not
cause oxygen limitation, overflow metabolism, and pH drop
(Panula-Perälä et al. 2008). This, in turn, leads to higher pro-
tein expression in combination with enhanced metabolic ac-
tivity (Ukkonen et al. 2011). Thus, a higher synthesis rate of
the metabolite can be achieved. This could, for example, al-
ready be demonstrated by the increased heterologous produc-
tion of valinomycin in E. coli (Li et al. 2014).
Furthermore, when using B. subtilis JK59-1, it could be
shown that the 6dEB metabolite accumulates during the last
24 h of cultivation. The productivity of the heterologous host
even rose since 6dEB titers could be more than doubled dur-
ing that time with consistent cell density. This indicates that
the metabolite synthesis is not limited by the depletion of one
of the substrates and that the DEBS proteins are expressed at a
constant level.
In addition, 6dEB was exclusively detectable in the
medium but not in the cell extract. Thus, the metabolite
seems to be completely secreted into the supernatant. It is
noteworthy that such a secretory production is advanta-
geous, especially for simplified detection and downstream
processing.
Fig. 3 Comparison of modified B. subtilis JK59-1 strains with engineered
genetic background. a Growth curves (OD600) during cultivation for 64 h
(16 h pre- plus 48 h post-boostering) in EnBase® medium. b Quantitative
MRM analysis of secreted 6dEB of modified B. subtilis strains (t=48 h after
boostering). BsJK59-1: three individually controlled genes with optimized
RBSs; BsJK60: additional expression of ery_orf5 (TE II); BsJK62: with
lytC inactivation; BsJK63: with spoIIGA inactivation; BsJK68: deletion of
bacillaene synthase cluster; BsJK120: deletion of plipastatin synthase clus-
ter. N=3, therefore no quartiles, but the median is shown
Fig. 4 Influence of the prpBD knockout and feeding of sodium
propionate. a Growth curves (OD600) during cultivation for 64 h (16 h
pre- plus 48 h post-boostering) in EnBase® medium. b Quantitative
MRM analysis of secreted 6dEB of modified B. subtilis strains (t=48 h
after boostering). BsJK120: prpBD positive control; BsJK125: deletion of
prpBD operon. N=3, therefore no quartiles, but the median is shown
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To enhance 6dEB synthesis, the DEBS-specific TEII
encoded by ery-orf5 was chromosomally integrated in
B. subtilis JK59-1. In general, the function of these discrete
hydrolytic enzymes, which are quite often associated with
PKS and NRPS gene clusters, is to remove aberrant residues
blocking the megasynthase, to participate in substrate selec-
tion as well as to release intermediates and products
(Kotowska and Pawlik 2014). In recent studies, it could be
shown that the deletion of the DEBS-TEII gene in the native
host Saccharopolyspora erythraea led to both an increase of
the side product 8,8 ′-deoxyoleandolide (15-nor-6-
deoxyerythronolide B) and lower erythromycin production
(Hu et al. 2003). Furthermore, coexpression of this TEII in a
6dEB producing E. coli strain resulted in a doubled product
yield (Pfeifer et al. 2002). However, in contrast to our expec-
tations, B. subtilis JK60, which harbored the ery-orf5 gene
under the control of the acoA-promoter, showed a reduced
6dEB synthesis (−30 %) compared with the parental strain
B. subtilis JK59-1. The background of this negative effect is
not clear, and further investigations are necessary to gain bet-
ter insight into this unexpected outcome.
Corresponding to the optimization of B. subtilis ATCC
6051 as an expression host (Kabisch et al. 2012), lytC (the
major autolysin) as well as spoIIGA (involved in sporulation)
was deleted to improve the growth behavior. As expected, the
lytC knockout mutant B. subtilis JK62 showed a higher cell
density compared to the parental strain B. subtilis JK60 and
resulted in an enhanced 6dEB production (+30%). Production
levels could be further increased by the additional deletion of
spoIIGA, although this knockout led to a reduced cell growth.
The enhancement of the 6dEB synthesis (+30%) in B. subtilis
JK63 could be an unspecific effect of optimized cell metabolic
processes due to the prevention of spore formation (Kabisch
et al. 2012).
In addition to these growth-related modifications, the dele-
tion of host-own PKS and NRPS gene clusters was performed
in order to reduce the metabolic burden and potential cross
talk. The srfAA–D genes (~26 kb) responsible for surfactin
production (NRP) were already removed by the chromosomal
integration of the DEBS operon. Thus, the influence of this
knockout on 6dEB production cannot be assessed. Contrary to
our expectations, the deletion of the bacillaene synthase clus-
ter (pksA–R, ~76 kb) in B. subtilis JK68 did not enhance the
product yield compared to its parental strain JK63. This might
be due to different substrates, which are necessary for 6dEB
(propionyl- and methylmalonyl-CoA) and bacillaene (mainly
malonyl-CoA) synthesis, whereby no direct competition for
starter and extender units exists. The ppsA–E knockout mutant
B. subtilis JK120 also showed no significant increase in 6dEB
formation compared to the JK68 control strain. Although the
removal of genes of the secondary metabolism did not en-
hance cell growth and has only a weak effect on 6dEB syn-
thesis, these deletions might be of particular interest for an
industrial production strain. Due to safety reasons and
simplification of the downstream process, Bclean^
hosts which do not produce unwanted side products
are preferred.
As a l ready ment ioned , p rop iony l - and (2S) -
methylmalonyl-CoA are necessary for 6dEB synthesis.
B. subtilis is capable of propionyl-CoA synthesis either from
the isoleucine and valine degradation pathway or directly from
propionate (Fig. 5). The starter unit propionyl-CoA can be
either metabolized to succinate (via PrpB and PrpD) or con-
verted to (2S)-methylmalonyl-CoA. Our data indicate that
B. subti l is provides a significant propionyl- and
methylmalonyl-CoA pool, but the native precursor concentra-
tion is not sufficient for an optimal 6dEB production. Thus,
propionate feeding was not mandatory but conductive, and the
positive effect of this supplementation could be enhanced by
the deletion of the propionyl-CoA degradation pathway. Both
procedures resulted in a better propionyl-CoA availability
which in turn led to higher intracellular (2S)-methylmalonyl-
CoA levels and thus to a more efficient 6dEB biosynthesis.
On the one hand, DEBS is one of the best investigated PKS
systems (Khosla et al. 2007). Since the substrates, the struc-
ture of the enzymatic complex, and the mechanism of the
Fig. 5 Metabolic pathways of
B. subtilis: connecting the
propionate metabolism to
heterologous 6dEB production.
The map has been constructed
from the KEGG Pathway
Database [http://www.genome.jp/
kegg/pathway.html#metabolism]
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biosynthesis of 6dEB are known, it is a suitable candidate for a
reference system. On the other hand, due to its complexity (28
active sites distributed among three linked proteins) and the
size of the corresponding gene cluster (~30 kb), cloning and
heterologous expression are challenging. Nevertheless, it is
demonstrated that B. subtilis is able to functionally express
the eryAI–III genes, when the three DEBS genes with opti-
mized RBS were individually expressed by separate pro-
moters under fed-batch cultivation conditions. Although the
final 6dEB production titer is not comparable with those
reached by optimized E. coli strains (Zhang et al. 2010), this
study indicates that B. subtilis is a suitable host for the secre-
tory production of a complex polyketide. To our knowledge,
this is the first communication for the heterologous production
of a polyketide in the Gram-positive bacterium B. subtilis.
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